Form 8-K NovoCure Ltd For: Oct 15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
H.C. Wainwright Upgrades NovoCure Ltd. (NVCR) to Buy
October 16, 2024 6:06 AM EDTH.C. Wainwright analyst Emily Bodnar upgraded NovoCure Ltd. (NASDAQ: NVCR) from Neutral to Buy with a price target of $30.00.
The analyst comments "Optune Lua receives FDA approval with favorable label based on the LUNAR Phase 3 study. Yesterday after market close, Novocure announced that the FDA has approved Optune Lua for the treatment of metastatic NSCLC for use concurrently with PD-(L)1 inhibitors or docetaxel in patients who have progressed on or after a platinum based regimen. The approval was based on the Phase 3 LUNAR study which demonstrated that there was a 3.3... More
